Spectral Medical Inc.
TSX:EDT.TOMedical - Diagnostics & Research
-$0.02 today
- Market cap
- $306.00M
- Beta
- 0.23
- P/E (TTM)
- -10.5
- EPS (TTM)
- -$0.13
Volume 0.02M
Average 0.06M
EDT.TO Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Spectral Medical Inc.TSX: EDT.TO
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 14.9% from a year ago
Cash & equivalents stood at CA$1.92M at the end of Q1 FY2026, up 14.9% from a year earlier and down 52.9% from the prior quarter. Over 3 fiscal years it compounded at -21.5% a year.
Context
- Cash & equivalents amounted to 41.9% of total assets at the end of Q1 FY2026, up 0.8 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +14.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
CAD · from the balance sheet
- Latest · FY2025
- 4.07M CAD
- Year-over-year change
- +36.2%
- 4-year CAGR
- -17.7%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.07M | +36.2% |
| FY2024 | 2024-12-31 | 2.99M | +1.2% |
| FY2023 | 2023-12-31 | 2.95M | -64.9% |
| FY2022 | 2022-12-31 | 8.41M | -5.4% |
| FY2021 | 2021-12-31 | 8.89M | — |
Cash & Equivalents vs competitors
How EDT.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +14.9% is the 4th highest of 8, against a peer median of +8.4%.
- Cash & equivalents amounts to 41.9% of total assets for EDT.TO, versus a peer median of 37.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CA$364.68M CAD | +220.4% | -18.6% | 32.6% | |
| Mar 2026 | CA$112.48M CAD | -18.4% | -28.0% | 18.7% | |
| Mar 2026 | $58.54M USD | +113.2% | +48.1% | 40.2% | |
| Mar 2026 | CA$51.52M CAD | -30.5% | +58.3% | 37.2% | |
PRN.TOProfound Medical Corp. | Mar 2026 | $50.33M USD | +8.4% | +8.6% | 68.5% |
| Mar 2026 | $40.08M USD | +76.7% | +15.6% | 55.9% | |
| Mar 2026 | $6.41M USD | -70.8% | -36.2% | 4.2% | |
| Mar 2026 | CA$1.92M CAD | +14.9% | -21.5% | 41.9% | |
| Peer median (excluding EDT.TO) | — | +8.4% | +8.6% | 37.2% | |
Competitors are the stored peer set for EDT.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 8.89M | 8.41M | 2.95M | 2.99M | 4.07M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 205K | 1.06M | 186K | 451K | 205K |
| Inventory | 293K | 340K | 366K | 229K | 377K |
| Other Current Assets | 875K | 192K | 135K | 0 | 0 |
| Total Current Assets | 10.26M | 10.09M | 4.13M | 4.46M | 5.29M |
| Property, Plant & Equipment (Net) | 1.06M | 701K | 893K | 687K | 474K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 228K | 211K | 193K | 175K | 333K |
| Long-term Investments | 0 | 998K | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Assets | 1.29M | 1.91M | 1.09M | 862K | 807K |
| Total Assets | 11.56M | 12M | 5.21M | 5.32M | 6.1M |
| Account Payables | 444K | 1.65M | 1.6M | 990K | 1.34M |
| Short-term Debt | 0 | 3.57M | 264K | 14.43M | 16.44M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 689K | 696K | 727K | 380K | 693K |
| Other Current Liabilities | 602K | 337K | 7.19M | 9.74M | 47.37M |
| Total Current Liabilities | 2.3M | 6.63M | 10.24M | 27.45M | 66.27M |
| Long-term Debt | 0 | 3.49M | 7.68M | 0 | 4.29M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 4.68M | 4.01M | 3.34M | 5.05M | 4.56M |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 470K |
| Total Non-current Liabilities | 5.17M | 7.92M | 11.52M | 5.42M | 9.55M |
| Total Liabilities | 7.47M | 14.55M | 21.76M | 32.87M | 75.82M |
| Common Stock | 84.36M | 87.05M | 87.06M | 90.57M | 95.93M |
| Retained Earnings | (98.49M) | (109.78M) | (125.44M) | (140.84M) | (188.53M) |
| Accumulated OCI | 10.24M | 11.4M | 12.91M | 12.58M | 12.66M |
| Other Stockholders Equity | 0 | 0 | 1 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 4.08M | (2.55M) | (16.55M) | (27.55M) | (69.72M) |
| Total Debt | 582K | 7.57M | 8.56M | 14.93M | 21.09M |
| Net Debt | (8.31M) | (1.77M) | 5.61M | 11.94M | 17.02M |
Spectral Medical Inc.
TSX:EDT.TO
Intrinsic Alpha fair value
Locked
Current Price
$1.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.